Welcome to our dedicated page for Paragon 28 news (Ticker: FNA), a resource for investors and traders seeking the latest updates and insights on Paragon 28 stock.
Overview of Paragon 28 Inc
Paragon 28 Inc (FNA) is a specialized medical device company dedicated exclusively to the foot and ankle orthopedic segment. Established in 2010 with a clear mission to blend surgical innovation and quality, the company has built a comprehensive portfolio of surgical solutions targeting complex foot and ankle procedures. Utilizing advanced technologies in orthopedic implants and surgical instrumentation, Paragon 28 aims to set a benchmark in innovation and operational efficiency within the medical device industry.
Mission and Core Values
From its humble beginnings as a small, family-based business, Paragon 28 has consistently maintained its core ideals of innovation, quality, and dedicated service. The company's name is a tribute to its exclusive focus on foot and ankle surgery, with the number '28' symbolizing the anatomical complexity of the human foot. Central to its mission is the drive to advance the science of foot and ankle surgery by integrating diverse surgical philosophies from global thought leaders, ensuring that each surgical solution meets stringent biomechanical and clinical standards.
Comprehensive Product Portfolio
Paragon 28 offers an extensive suite of nearly 80 proprietary surgical product systems. These include a range of orthopedic devices such as plates, plating systems, screws, staples, and nails. These products are meticulously designed to address a variety of foot and ankle procedures including:
- Ankle reconstruction and fixation for complex fractures and musculoskeletal trauma
- Fracture fixation solutions that ensure stability and promote healing
- Procedural instrumentation for deformity corrections, hallux valgus, hammertoe, and flatfoot conditions
- Innovative solutions for specialized conditions such as Charcot foot and progressive collapsing foot deformity
Operational Excellence and Distribution
The company leverages a dedicated and highly trained sales and distribution network to ensure that its advanced orthopedic devices reach a wide network of surgical centers and hospitals, primarily within the United States. This customer-centric approach, combined with efficient operational practices, allows Paragon 28 to address the dual challenges of increasing pricing pressures and reimbursement complexities within the healthcare sector.
Competitive Position and Industry Impact
Operating within the dynamic and competitive landscape of orthopedics, Paragon 28 has distinguished itself through its unwavering focus on the foot and ankle segment. By prioritizing innovation and tailoring its product offerings to meet the precise needs of both patients and surgeons, the company has established a strong operational niche. Its strategy of blending global surgical insights with a rigorous quality framework enables it to create products that are not only clinically relevant but also easily reproducible in diverse surgical settings. This distinctive positioning highlights the company’s commitment to improving patient outcomes while maintaining operational efficiency.
Strategy and Business Model
Paragon 28's business model is anchored in its commitment to three primary pillars:
- Creation and Innovation: Investing in research and development to refine surgical techniques and develop devices that address specific clinical challenges in the foot and ankle spectrum.
- Focused Service: Establishing a robust distribution network that ensures timely delivery and superior customer service, which is critical for high-stakes surgical environments.
- Efficient Practices: Implementing operational efficiencies to navigate challenges related to evolving reimbursement frameworks and pricing pressures, thereby sustaining a cycle of quality and innovation.
Expertise and Authoritativeness
The company's process of integrating varied surgical philosophies into its product design reflects deep industry expertise. Paragon 28’s commitment to ongoing research and development, along with its emphasis on user-friendly yet technologically advanced products, positions it as a trusted name among orthopedic surgeons. The company’s continuous efforts in refining its product systems set a high standard of care in the specialized field of foot and ankle surgery.
Understanding the Technology and Innovation
In the realm of medical devices, technological innovation is crucial. Paragon 28 harnesses cutting-edge manufacturing techniques and research-driven insights to build devices that enhance surgical precision and reliability. This detailed approach ensures that each product not only conforms to current clinical requirements but also anticipates the nuanced challenges surgeons face during delicate procedures. The application of advanced orthopedic implant technologies and state-of-the-art design principles underscores the company’s commitment to facilitating optimal patient outcomes.
Market Significance and Industry Relevance
Although Paragon 28 operates within a specialized niche of the orthopedic implant market, the company’s influence is profound due to its unwavering focus on quality, innovation, and customer service. Its strategic approach, combined with a suite of versatile surgical solutions, effectively addresses critical gaps in the foot and ankle surgical procedural space. This specialization allows the company to serve a targeted customer base that includes orthopedic surgeons, hospitals, and outpatient surgical centers, all of which rely on dependable and innovative surgical solutions to improve patient care.
Conclusion
In summary, Paragon 28 Inc stands as a comprehensive, innovation-driven entity in the orthopedic medical device arena. Its focused mission, extensive product portfolio, and commitment to blending global surgical insights with efficient, reliable service have positioned it as a pivotal player in addressing the challenges of foot and ankle surgery. Through its attention to detail in both product development and operational execution, Paragon 28 offers a detailed case study of how concentrated expertise can drive significant advancements in medical technology.
Paragon 28 (NYSE: FNA), a specialized foot and ankle orthopedic medical device company, has announced a significant milestone in its pending acquisition by Zimmer Biomet (NYSE: ZBH). The waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) has expired, marking a important step in the regulatory approval process.
The transaction still requires additional approvals, including stockholder approval from Paragon 28 and other regulatory clearances. Both companies anticipate the merger to be completed in the first half of 2025, subject to satisfying remaining closing conditions.
Paragon 28 (NYSE: FNA), a foot and ankle orthopedic medical device company, will showcase its latest product innovations at the American Academy of Orthopaedic Surgeons (AAOS) conference from March 10th-14th. The company will feature several recently launched products:
- SMART 28℠ Case Management Portal with SMART Bun-Yo-Matic℠: An AI-powered digital platform for surgical planning
- APEX 3D S™ Stemmed Tibial Implant: Features a 12mm stem with specialized surface treatments for fixation
- Phantom® Fibula Nail System: A minimally invasive implant for fibula fracture stabilization
- R3FLEX™ Stabilization System: A dynamic syndesmotic repair solution
- FJ2000™ Power Console: A sterile-packed, single-use power system
- PRECISION® MIS Bunion System: A minimally invasive solution for bunion correction
Zimmer Biomet reported strong Q4 2024 financial results with net sales of $2.023 billion, up 4.3% year-over-year (4.9% constant currency). Full-year net sales reached $7.679 billion, increasing 3.8% (4.8% constant currency).
Q4 net earnings were $239.4 million ($462.4 million adjusted), with diluted EPS of $1.20 ($2.31 adjusted). Full-year net earnings totaled $903.8 million ($1.630 billion adjusted), with diluted EPS of $4.43 ($8.00 adjusted).
The company announced plans to acquire Paragon 28, expanding into the $5 billion foot and ankle segment. Notable achievements include FDA approval for the Oxford® Cementless Partial Knee and OsseoFit™ Stemless Shoulder System. For 2025, the company projects revenue growth of 1.0-3.5% (3.0-5.0% constant currency) and adjusted EPS of $8.15-$8.35.
Zimmer Biomet (NYSE: ZBH) has announced a definitive agreement to acquire Paragon 28 (NYSE: FNA) for $13.00 per share in cash, representing an equity value of approximately $1.1 billion and enterprise value of $1.2 billion. Paragon 28 shareholders will receive a non-tradeable contingent value right (CVR) worth up to $1.00 per share if certain revenue milestones are achieved in fiscal year 2026.
The acquisition expands Zimmer Biomet's presence in the ~$5 billion foot and ankle segment. Paragon 28, established in 2010, offers surgical solutions across major foot and ankle segments. The transaction is expected to immediately accelerate Zimmer Biomet's revenue growth, with Paragon 28's projected 2024 net revenue between $255.9-256.2 million, representing 18.2-18.4% growth.
The deal is anticipated to close in first half of 2025, subject to regulatory approvals and Paragon 28 stockholder approval. It is expected to be approximately 3% dilutive to adjusted EPS in 2025, 1% dilutive in 2026, and accretive within 24 months of closing.
Paragon 28 (NYSE: FNA), a leading medical device company in the foot and ankle orthopedic market, announced its preliminary unaudited net revenue for the fourth quarter and full year ended December 31, 2024.
For the fourth quarter of 2024, net revenue is expected to range between $71.5 million and $71.8 million, reflecting a growth rate of approximately 18.0% to 18.5% compared to the same period in 2023. For the full year of 2024, net revenue is anticipated to be between $255.9 million and $256.2 million, representing a growth rate of about 18.2% to 18.4% compared to the full year of 2023.
These figures are preliminary and unaudited, subject to adjustments following the completion of quarter-end and year-end closing procedures, and further financial review. Paragon 28's independent registered public accounting firm has not audited, reviewed, or compiled this preliminary financial information.
CEO Albert DaCosta noted that 2024 was a transformative year with significant achievements in growth, innovation, and operational efficiency, positioning the company for sustainable, profitable growth in the future.
Paragon 28 (NYSE: FNA), a specialized medical device company focused on foot and ankle orthopedics, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's Chairman and CEO Albert DaCosta, along with CFO & EVP of Supply Chain Operations Chadi Chahine, will deliver a presentation on Monday, January 13, 2025, at 7:30 a.m. Pacific Time / 8:30 a.m. Mountain Time.
Interested parties can access the presentation through a live webcast, and an archived recording will be made available on the investor relations section of Paragon 28's website at ir.paragon28.com.
Paragon 28 (NYSE: FNA), a foot and ankle surgical solutions provider, has appointed Dave Demski as an independent director, expanding its board from eight to nine members. Demski brings over two decades of orthopedic executive leadership experience, having most recently served as President and CEO of Globus Medical from 2017 to 2022. His background includes roles as CFO, COO, and President of Emerging Technologies at Globus Medical. Currently, he serves on the board of Alphatec Spine and previously served on Axonics' board until its acquisition by Boston Scientific in 2024. Demski holds a B.S. in Business Administration from the University of Michigan and an MBA from Stanford.
Cohen Milstein has announced a securities class action lawsuit against Paragon 28 (NYSE:FNA), a medical device company, regarding alleged false and misleading statements about financial statements and internal controls. The lawsuit covers investors who purchased shares between May 5, 2023, and September 20, 2024. Investors who suffered significant losses during this period have until November 29, 2024, to request appointment as lead plaintiff. The complaint, filed in the U.S. District Court for the District of Colorado, alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 by current and former officers.
Paragon 28 (NYSE: FNA), a specialized medical device company focusing on foot and ankle orthopedics, has announced its participation in the 36th Annual Piper Sandler Healthcare Conference. Chairman and CEO Albert DaCosta and CFO Chadi Chahine will engage in a fireside chat on Tuesday, December 3, 2024, at 8:30 a.m. Eastern Time. The presentation will be accessible via live webcast and archived recording on the company's investor relations website at ir.paragon28.com.
A class action securities lawsuit has been filed against Paragon 28 (NYSE:FNA), a medical device company, in the U.S. District Court for the District of Colorado. The lawsuit alleges that the company and certain officers made false and misleading statements regarding financial statements and internal controls between May 5, 2023 and September 20, 2024. Cohen Milstein Sellers & Toll PLLC is urging affected shareholders who suffered significant losses during this period to contact them by November 29, 2024 to potentially serve as lead plaintiff. Investors are not required to file as lead plaintiff to participate in any potential recovery.
FAQ
What is the current stock price of Paragon 28 (FNA)?
What is the market cap of Paragon 28 (FNA)?
What does Paragon 28 Inc specialize in?
What types of products does Paragon 28 offer?
How does Paragon 28 generate revenue?
What are the core values of Paragon 28 Inc?
How does Paragon 28 maintain industry expertise?
What distinguishes Paragon 28 in the competitive orthopedic market?
Who are the primary customers of Paragon 28?
How does Paragon 28 address the challenges in the healthcare market?
